Informaは企業と専門家を数百の方法でサポートしています。

私たちの国際的なライブイベント、世界をリードする研究出版物、革新的なデジタルサービスのポートフォリオは、専門家が成功するために必要な知識と人脈を提供しています。

TIDES Asia: Oligonucleotide & Peptide Therapeutics
24-26 Feb, 2027
Grand Nikko Tokyo DaibaTokyo

Luiza Jedlina, PhD
Aptahem AB における Chief Scientific Officer
スピーカー

プロフィール

Luiza Jedlina, PhD, is Chief Scientific Officer of Aptahem AB (publ), a Swedish clinical-stage biotechnology company developing RNA aptamer therapeutics for acute, life-threatening conditions in which coagulation and inflammation are coupled. She holds a doctorate in parasitology and molecular immunology and a master's degree in toxicology, with 25 years in pharmacology and immunology spanning vaccine development, molecular cloning and diagnostic assay design. She is the named inventor behind Apta-1, Aptahem's lead drug candidate (European patent EP3691655B1), and has led the programme from discovery and preclinical development into first-in-human evaluation. Her work on Apta-1 has been published in the British Journal of Pharmacology (2025) and Cells (2024).